Amsterdam Neuroscience has integrated the clinical trial expertise from different therapeutic areas within Amsterdam
UMC into a peer-groups of clinical advisors and investigators, i.e. the so-called Clinical Trial Teams. Together with the experts from the Brain Research Center Amsterdam (see here) the clinical trial teams of Amsterdam UMC provide support and know-how towards organizing and executing industry sponsored clinical trials.
The emphasis is on rigorous, academically informed experimental medicine capitalizing on our extensive clinical and academic facilities, and allowing us to undertake a broad range of research from first-in-patient studies (i.e. phase 1B) all the way up to large national and international multicenter clinical trials (phase 2A en 2B) and cohort studies.
Streamlining the process of taking therapies from bench-to-bedside is at the heart of the Amsterdam Neuroscience. The scope of the IAO clinical trial teams is to design, conduct and report in both early and later phase clinical trials and cohort studies in neuroscience.
The IAO teams focus in particular on development pathways and the evaluation of new health technologies in pharmaceuticals, particular in Alzheimer disease, Multiple Sclerosis, Parkinson’s disease, neuroinflammation, stroke, and neurosurgical and interventional procedures (including deep-brain stimulation and acute treatment of stroke), but also on biomarkers to refine treatment strategies. In addition we are currently our translational research service offering in the field of Psychiatry.